Johnson & Johnson buy melinda
Summary
This prediction ended on 11.03.20 with a price of €117.78. With a performance of -5.54%, the BUY prediction for Johnson & Johnson by melinda closed slightly in the red. A total of €3.25 was paid as dividends for this prediction. melinda has 50% into this predictionJohnson Johnson is a multinational company that focuses on the development, manufacturing, and marketing of a wide range of consumer health products, medical devices, and pharmaceuticals. The company was founded in 1886 and is headquartered in New Jersey, USA. It operates in more than 60 countries and has a diverse portfolio of popular brands including Band-Aid, Tylenol, and Neutrogena. As of 2021, Johnson Johnson has a market capitalization of over $435 billion and is listed on the New York Stock Exchange under the symbol JNJ.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Johnson & Johnson | 1.671% | 1.671% | -5.889% | 1.285% |
| iShares Core DAX® | -0.922% | -1.993% | 13.399% | 16.075% |
| iShares Nasdaq 100 | 0.371% | -0.868% | 41.541% | 46.938% |
| iShares Nikkei 225® | 2.224% | -5.187% | 20.497% | 4.643% |
| iShares S&P 500 | -0.026% | -0.918% | 30.410% | 42.418% |
According to melinda what are the pros and cons of Johnson & Johnson for the foreseeable future?
Pros
Cons
Comments by melinda for this prediction
In the thread Johnson & Johnson diskutieren
SecteurProduits pharmaceutiques Agenda 28/02 | 17:00 Présentation
Johnson & Johnson figure parmi les 1ers fabricants mondiaux de produits de soins. Les
produits pharmaceutiques (47,4%): médicaments destinés au traitement des maladies cardio-vasculaires, oncologiques, gastro-intestinaux, immunitaires, neurologiques, dermatologiques, etc.
- produits et équipements médicaux (34,8%): systèmes de diagnostic, produits orthopédiques et gynécologiques, matériel chirurgical, etc.
- produits de grande consommation (17,8%): Médicaments OTC, produits ophtalmologiques (marque Acuvue), circuits de nutrition, soins de la personne (marques RoC, Neutrogena, etc.), d ' hygiène féminine, de soins pour bébés, etc.
En 2017, Johnson & Johnson dispose de 125 sites de production d'implants aux budgets (40), en Amérique du Nord (14), en Europe (37), en Afrique et en Asie-Pacifique (34).
La répartition géographique du CA est la suivante: Budget Unis (52,1%), Europe (22,4%), Asie-Pacifique et Afrique (17,6%) et autres (7,9%).
In the thread Trading Johnson & Johnson
Stopped prediction by melinda for Johnson & Johnson
Johnson & Johnson
24.01.23
24.01.24
25.01.24
Johnson & Johnson
11.03.20
04.11.21
05.11.21
Johnson & Johnson
06.01.18
06.07.18
06.07.18
Johnson & Johnson
07.01.14
07.07.14
07.07.14
Johnson & Johnson
02.08.10
02.02.11
02.02.11